3 results
To improve response rate of primary treatment of extensive chronic GvHD with the addition of MPA to the reference treatment CsA+PDN (comparator)Primary ObjectiveTo improve remission rates with cyclosporine A+ prednisone + Myfortic® (CsA+PDN+MPA)…
The purpose of the study is to assess the efficacy and safety in adolescents of AFQ056 in treating behavioral symptoms characteristic of patients with FXS. Data from this study will be used to support the registration of AFQ056 in this population…
The primary objectives are to investigate which determinants (primarily carnitine status) determine the effect of carnitine supplementation on metabolic flexibility and insulin sensitivity in patients with type 2 diabetes. Furthermore, a secondary…